Françoise Rothé
YOU?
Author Swipe
View article: Supplementary Figure 6 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Figure 6 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Figure 6. Immune infiltration at the gene expression and protein levels according to PD-L1 status assessed on tubo-ovarian samples.
View article: Supplementary Figure 5 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Figure 5 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Figure 5. Biological pathways and immune and stroma cells abundance estimation in metastases and tubo-ovaries in Australian Ovarian Cancer Study (AOCS) dataset.
View article: Data from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Data from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Purpose:To describe PD-L1 expression across tissue types and its associated tumor microenvironment and to investigate how it affects its predictive value for response to pembrolizumab in treatment-naïve patients with ovarian cancer include…
View article: Supplementary Data 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Data 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Data 1. Differentially expressed genes and Gene Set Enrichment Analyses between PD-L1 positive and negative samples and between tubo-ovarian primary and metastases in the NeoPembrOv cohort.
View article: Supplementary Figure 7 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Figure 7 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Figure 7. Correlation between CD274 gene expression and 42 hallmarks signatures.
View article: Supplementary Table 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Table 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Table 1. Clinic-pathological characteristics in the whole population and in the biomarker evaluable population within NeoPembrOV clinical trial.
View article: Supplementary Figure 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Figure 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Figure 1. Flow chart of the population and biomarkers analyses.
View article: Supplementary Figure 2 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Figure 2 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Figure 2. Flow chart of the biomarkers analyzed population.
View article: Supplementary Data 2 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Data 2 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Data 2. Differentially expressed genes and Gene Set Enrichment Analyses between tubo-ovarian primary and metastases in the AOCS cohort.
View article: Supplementary Table 2 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Table 2 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Table 2. Clinic-pathological characteristics according to tissue type subgroups within the NeoPembrOv clinical trial.
View article: Supplementary Data 3 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Data 3 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Data 3. Correlation between CD274 and hallmarks gene sets in NeoPembrOv and Australian Ovarian Cancer Study (AOCS).
View article: Supplementary Methods 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Methods 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Methods 1. First antibody panel (T panel) and second antibody panel (TLS panel).
View article: Supplementary Figure 4 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Figure 4 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Figure 4. Progression free survival according to treatment arm and PD-L1 score assessed on tubo-ovarian samples.
View article: Supplementary Figure 3 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Supplementary Figure 3 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Supplementary Figure 3. Overall survival according to treatment arm and PD-L1 score.
View article: Immuno-Radiotherapy Enhances Tumor Control and Induces Abscopal Responses in a Humanized Mouse Model
Immuno-Radiotherapy Enhances Tumor Control and Induces Abscopal Responses in a Humanized Mouse Model Open
Radiation therapy (RT) offers a tool to enhance immune checkpoint inhibitor (ICI) efficacy, yet its immunomodulatory potential remains poorly understood. Using a hematopoietic stem cell-humanized NOG mouse model bearing ICI-responsive rena…
View article: Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00 Open
Phosphorylation of the JNK (pJNK) protein promotes an immunosuppressive tumor microenvironment (TME), enhancing aggressiveness in inflammatory triple-negative breast cancer (TNBC). This study evaluated the role of JNK signaling using a gen…
View article: Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial Open
Purpose: To describe PD-L1 expression across tissue types and its associated tumor microenvironment and to investigate how it affects its predictive value for response to pembrolizumab in treatment-naïve patients with ovarian cancer includ…
View article: 72P Predictive value of spatially-derived archetypes and tertiary lymphoid structure signature in the NeoTRIP trial
72P Predictive value of spatially-derived archetypes and tertiary lymphoid structure signature in the NeoTRIP trial Open
View article: Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial Open
Background Immunotherapy is becoming a standard of care for non-metastatic muscle-invasive bladder cancer (MIBC). The optimal chemotherapy partner for chemo-immunotherapy combinations remains unknown. We evaluated the efficacy and safety o…
View article: Supplementary Table S3 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Table S3 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Gene set enrichment analysis on Hallmark gene sets, on genes ranked based on the correlation between gene expression and FDG-PET uptake described by SUVmax (positive normalized enrichment score – NES – for positive correlation, negative NE…
View article: Supplementary Table S8 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Table S8 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Gene set enrichment analysis on Reactome gene sets, comparing, within the 89Zr-trastuzumab class “high”, metabolic response (positive normalized enrichment score – NES) and lack of metabolic response (negative NES).
View article: Supplementary Figure S2 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Figure S2 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
CONSORT diagram showing the patient selection for the present analysis in the ZEPHIR trial
View article: Supplementary Figure S4 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Figure S4 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Comparison of abundance scores of immune populations and stromal cell types with MCP-counter according to A, ZrT class (dichotomized into “high” and “low”), and B, metabolic response.
View article: Supplementary Figure S6 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Figure S6 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Forest plots for pCR in I-SPY2, HER2-positive population, multivariable analysis controlling for hormone receptor status and treatment arm.
View article: Supplementary Table S2 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Table S2 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Gene set enrichment analysis on Reactome gene sets, comparing 89Zr-trastuzumab classes “high” (positive normalized enrichment score – NES) and “low” (negative NES).
View article: Supplementary Table S1 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Table S1 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Gene set enrichment analysis on Hallmark gene sets, comparing 89Zr-trastuzumab classes “high” (positive normalized enrichment score – NES) and “low” (negative NES).
View article: Supplementary Table S9 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Table S9 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
[89Zr]trastuzumab (ZrT) class and metabolic response signatures
View article: Supplementary Figure S3 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Figure S3 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Levels of TILs (%) according to ZrT class (dichotomized into “high” and “low”), and metabolic response.
View article: Supplementary Table S4 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Table S4 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Gene set enrichment analysis on Reactome gene sets, on genes ranked based on the correlation between gene expression and FDG-PET uptake described by SUVmax (positive normalized enrichment score – NES – for positive correlation, negative NE…
View article: Supplementary Table S7 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Supplementary Table S7 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial Open
Gene set enrichment analysis on Hallmark gene sets, comparing, within the 89Zr-trastuzumab class “high”, metabolic response (positive normalized enrichment score – NES) and lack of metabolic response (negative NES).